Featured Tickers:
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Harmony Biosciences Holdings, Inc. or Avadel Pharmaceuticals plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Harmony Biosciences Holdings, Inc. and Avadel Pharmaceuticals plc compare based on key financial metrics to determine which better meets your investment needs.
About Harmony Biosciences Holdings, Inc. and Avadel Pharmaceuticals plc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Latest Pharmaceuticals and Harmony Biosciences Holdings, Inc., Avadel Pharmaceuticals plc Stock News
As of November 28, 2025, Harmony Biosciences Holdings, Inc. had a $2.0 billion market capitalization, compared to the Pharmaceuticals median of $434.0 million. Harmony Biosciences Holdings, Inc.’s stock is up 3.2% in 2025, up 3.5% in the previous five trading days and up 1.67% in the past year.
Currently, Harmony Biosciences Holdings, Inc.’s price-earnings ratio is 11.1. Harmony Biosciences Holdings, Inc.’s trailing 12-month revenue is $825.9 million with a 22.5% net profit margin. Year-over-year quarterly sales growth most recently was 28.8%. Analysts expect adjusted earnings to reach $4.036 per share for the current fiscal year. Harmony Biosciences Holdings, Inc. does not currently pay a dividend.
As of November 28, 2025, Avadel Pharmaceuticals plc had a $2.1 billion market cap, putting it in the 57th percentile of all stocks. Avadel Pharmaceuticals plc’s stock is up 103.7% in 2025, down 7% in the previous five trading days and up 91.53% in the past year.
Currently, Avadel Pharmaceuticals plc does not have a price-earnings ratio. Avadel Pharmaceuticals plc’s trailing 12-month revenue is $248.5 million with a -0.1% net profit margin. Year-over-year quarterly sales growth most recently was 55.0%. Analysts expect adjusted earnings to reach $0.277 per share for the current fiscal year. Avadel Pharmaceuticals plc does not currently pay a dividend.
How We Compare Harmony Biosciences Holdings, Inc. and Avadel Pharmaceuticals plc Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Harmony Biosciences Holdings, Inc. and Avadel Pharmaceuticals plc’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions